| 1 |
ION363 (ulefnersen) |
3 |
-
antisense oligonucleotide therapy for genetic FUS ALS
- sites in CA, MD, MA, MO, NY, OH, UT
|
Ionis Pharmaceuticals, Inc. |
| 2 |
MN-166 (ibudilast) |
2/3 |
-
50% chance of placebo for 12 months followed by an open label extension for 6 months
- sites in CA, FL, GA, IN, MD, MN, NY, NC, PA, VA
|
MediciNova |
| 3 |
RAPA-501 |
2/3 |
-
no placebo
- autologous hybrid TREG/Th2 cells delivered intravenously
- Expanded Access Program also available for those ineligible for this trial
- site in MA
|
Rapa Therapeutics LLC |
| 4 |
VHB937 |
2 |
- 33% chance of placebo for 40 weeks treatment followed by an open label extension
-
intravenous delivery of an antibody designed to activatea protein called TREM2
- site in TX
|
Novartis Pharmaceuticals |
| 5 |
ranolazine |
2
|
- placebo controlled trial evaluating two doses of ranolazine
- site in FL, KS, MO
|
Swathy Chandrashekhar, MD |
| 6 |
AMT-162 |
1/2 |
-
no placebo
-
gene therapy for SOD1 relatedALS
-
one-time intrathecal injection, with up to five years of follow-up
-
participants cannot be on tofersen at trial initiation
- sites in CA, MA, NY sur
|
UniQure Biopharma B.V. |
| 7 |
istradefylline and acute intermittent hypoxia |
1/2 |
-
crossover study: all trial volunteers will receive placebo and all trial volunteers will receive active treatment at different timepoints
- site in FL
|
University of Florida |
| 8 |
CNS10-NPC-GDNF |
1 |
-
no placebo
- cells that produce GDNF (a growth factor) will be surgically
- transplanted into motor cortex of brain
- site in CA
|
Cedars-Sinai Medical Center |
| 9 |
|
1
|
|
Johns Hopkins University |
|
10
|
prosetin |
1 |
- placebo controlled trial lasting 14 days followed by open label extension
- oral drug designed to target MAP4 kinase
- site in MA
|
ProJenX |
|
11
|
|
N/A |
- no placebo
- trial is evaluating multi-site direct current stimulation
- site in MA
|
PathMaker Neurosystems Inc. |
| 12 |
Spinal Cord Associative Plasticity (SCAP) |
N/A
|
- trial being conducted at Bronx Veterans Administration Medical Center
- 2-4 month run in period to optimize SCAP, followed by a 2 week period of SCAP with or without hand exercises
- site in NY
|
VA Office of Research and Development
|
| 13 |
RAPA-501 |
EAP |
-
Expanded Access Program for people that are not eligible for trials
- autologous hybrid TREG/Th2 cells delivered intravenously
- sites in MA, NJ
|
Rapa Therapeutics LLC |
| 14 |
MN-166 (ibudilast) |
EAP |
- Expanded Access Program for people that are not eligible for trials
- Contact WideTrial to join interest list to participate and see additional contact info here
- site in FL
|
Mayo Clinic
|